Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for RVTY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -23.16M
March 31, 2026 -88.90M
December 31, 2025 -176.31M
September 30, 2025 -215.07M
June 30, 2025 -302.40M
March 31, 2025 -161.26M
December 31, 2024 -192.99M
September 30, 2024 -873.74M
June 30, 2024 -26.50M
March 31, 2024 -35.01M
December 31, 2023 -19.61M
September 30, 2023 -586.05M
June 30, 2023 -228.27M
March 31, 2023 -113.18M
December 31, 2022 -76.70M
September 30, 2022 -65.64M
June 30, 2022 -354.61M
March 31, 2022 -164.86M
December 31, 2021 -139.02M
September 30, 2021 2.755B
June 30, 2021 -257.72M
March 31, 2021 582.99M
December 31, 2020 73.43M
September 30, 2020 -155.94M
June 30, 2020 -95.77M
Date Value
March 31, 2020 -24.59M
December 31, 2019 -251.20M
September 30, 2019 170.13M
June 30, 2019 225.96M
March 31, 2019 5.235M
December 31, 2018 -57.27M
September 30, 2018 -109.03M
June 30, 2018 -25.94M
March 31, 2018 13.01M
December 31, 2017 816.69M
September 30, 2017 -15.68M
June 30, 2017 -2.586M
March 31, 2017 -16.18M
December 31, 2016 -62.37M
September 30, 2016 59.80M
June 30, 2016 -64.74M
March 31, 2016 -47.70M
December 31, 2015 -14.71M
September 30, 2015 -44.02M
June 30, 2015 -23.72M
March 31, 2015 -24.69M
December 31, 2014 154.63M
September 30, 2014 -47.01M
June 30, 2014 -65.14M
March 31, 2014 -11.55M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Agilent Technologies, Inc. 471.00M
Danaher Corp. 7.273B
Thermo Fisher Scientific, Inc. -1.571B
Waters Corp. -124.00M
Bio-Rad Laboratories, Inc. -27.60M